AstraZeneca's Latest Drug Offers Hope For Millions Battling Hard-To-Control Blood Pressure

On Saturday, AstraZeneca Plc (NASDAQ:AZN) released full results from the ​BaxHTN Phase 3 trial evaluating ​baxdrostat. The company released the topline data in July.

The study showed ​baxdrostat demonstrated a statistically significant and clinically meaningful reduction in mean seated systolic blood pressure (SBP) at two doses (2mg and 1mg) compared with placebo at 12 weeks. 

Results were seen in patients with hard-to-control (uncontrolled and resistant) hypertension who received baxdrostat or placebo on top of standard of care.

Also Read: UK Drug Pricing Talks Collapse, Drugmakers Reject Offer Citing ‘Uncompetitive’ System

The data was presented at the European Society of Cardiology (ESC) Congress 2025 and also simultaneously published in the New England Journal of Medicine.

Baxdrostat met the primary and all secondary endpoints in the BaxHTN Phase 3 trial, delivering meaningful and sustained blood ...